orabase and Voice-Disorders

Topics: Abscess; Adipose Tissue; Adolescent; Anti-Bacterial Agents; Carboxymethylcellulose Sodium; Combined Modality Therapy; Drainage; Female; Humans; Injections, Intralesional; Laryngoscopy; Lipectomy; Surveys and Questionnaires; Transplantation, Autologous; Vocal Cord Paralysis; Voice Disorders; Voice Quality

Trial vocal fold injection (TVFI) is employed diagnostically for patients with subtle glottic insufficiency to explore potential for improvement. Clinical experience demonstrates the time to and length of peak benefit of the TVFI is variable. Previous studies collected data 4 weeks or more after TVFI. The aim of this study was to compare subjectively successful and unsuccessful TVFI patient groups. It is hypothesized that patients with subjectively reported success will also have significant improvements in Voice Handicap Index-10 (VHI-10), phase closure percentage, and aerodynamic measures 2 weeks after trial augmentation.. Subjects with glottic insufficiency were included in this retrospective review if they underwent office-based, per-oral vocal fold injection augmentation specifically for trial purposes. Patients were divided into "successful" and "unsuccessful" groups based on their subjective experience during the 2-week post-TVFI period. VHI-10, subjective report, phase closure evaluation using frame-by-frame analysis, and aerodynamic data were collected pre- and 2 weeks post-TVFI.. Of the subjects, 15 of 23 (65%) reported a successful subjective improvement of their symptom, whereas 8 (35%) were unsuccessful (only partial improvement or no improvement). The number of subjects with an improvement in VHI-10 by 5 or more points was not significantly different between groups. The number of subjects that demonstrated complete, long phase closure was significantly higher in the successful group (P = 0.021).. The understanding of how to more precisely determine the success of TVFI remains incomplete. Subjective improvement of successful TVFI was captured with basic clinical questioning, yet the VHI-10 was unable to confidently demonstrate this reported success 2 weeks after TVFI.

Topics: Adult; Aged; Aged, 80 and over; Carboxymethylcellulose Sodium; Disability Evaluation; Female; Humans; Injections; Male; Middle Aged; Phonation; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Vocal Cord Paralysis; Vocal Cords; Voice Disorders; Voice Quality

To compare voice outcomes after vocal fold augmentation using a trial (temporary) vocal fold injection (VFI) versus long-term augmentation in patients diagnosed with vocal fold atrophy.. Retrospective, single-blinded study.. Nineteen patients diagnosed with vocal fold atrophy underwent trial VFI and subsequent long-term augmentation. Voice Handicap Index-10, acoustic, and aerodynamic measures were analyzed following trial and long-term augmentation procedures.. Forty-two percent (8/19) of patients had a good response to trial VFI (P < .0001); 58% (11/19) had a poor response to trial VFI (P = .95). Of the patients with good response to trial VFI, 75% (6/8) also had good response to long-term augmentation (P = .006), but 25% (2/8) reported a poor response to long-term treatment. Of the patients who had a poor response to trial VFI, 55% (6/11) also had a poor response to long-term treatment, but 45% (5/11) of patients reported good response after long-term augmentation.. This is the first study to provide comparative voice outcomes using both trial VFI and long-term augmentation for vocal fold atrophy. Additional critical evaluation of the value of trial VFI for vocal fold atrophy patients is suggested.

Topics: Aged; Aged, 80 and over; Atrophy; Carboxymethylcellulose Sodium; Female; Follow-Up Studies; Humans; Hyaluronic Acid; Injections, Intralesional; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Retrospective Studies; Single-Blind Method; Time Factors; Treatment Outcome; Vocal Cords; Voice Disorders; Voice Quality

Topics: Acellular Dermis; Carboxymethylcellulose Sodium; Drug Approval; Humans; Injections; United States; United States Food and Drug Administration; Vocal Cord Paralysis; Voice Disorders

Temporary vocal fold injection is a valuable procedure for vocal fold paralysis or paresis of uncertain permanency and as a trial augmentation to decide the value of vocal fold augmentation. A new material made from glycerin, carboxymethylcellulose, and water has recently been developed for temporary vocal fold augmentation. Eleven patients underwent vocal fold injection for the treatment of glottal incompetence with this material. The duration of effectiveness of this injection material was 2 to 3 months depending on the injection amount. This new material satisfies several requirements for an ideal temporary vocal fold injection material in terms of injectability, convenience, duration of effectiveness, and safety. The authors conclude that this new material is a good option for temporary vocal fold augmentation.

Topics: Adult; Aged; Carboxymethylcellulose Sodium; Female; Glottis; Glycerol; Humans; Injections; Male; Middle Aged; Needles; Stroboscopy; Treatment Outcome; Vocal Cord Paralysis; Vocal Cords; Voice Disorders; Voice Quality